Sphere Fluidics is set to launch the Cyto-Mine® Chroma in early 2025, a revolutionary update to its successful single-cell analysis platform, Cyto-Mine. For lab managers striving to boost productivity and streamline workflows, the new Chroma system delivers unmatched efficiency with its enhanced multiplexing capabilities and high throughput.
The introduction of a four-color laser system in Cyto-Mine Chroma allows researchers to conduct detailed, simultaneous analysis of multiple cell markers in a single step. This technology enables faster and more precise screening, reducing overall project timelines from months to weeks. By improving the early selection of high-performing cells, Cyto-Mine Chroma directly addresses common bottlenecks in cell line development and antibody discovery processes.
With upgradeable modules and flexible assay options, Cyto-Mine Chroma ensures labs can scale and adapt to new research demands, all while optimizing costs.
Benefits of the Cyto-Mine for lab managers:
- Significantly reduced project timelines through streamlined cell analysis
- Enhanced throughput with multiplexing for greater data capture in a single run
- Cost-effective operation with lower hands-on time and reagent use
- Flexible assay development to meet evolving research needs
- Upgrade modules for long-term scalability and adaptability
This article is a summary of a published press release provided by Sphere Fluidics
